Asuragen spins off new miRNA company

Austin-based Asuragen is spinning off its miRNA therapeutic intellectual property into a new company and seeding it with $3 million in cash. Working with Yale University researchers, Mirna will pursue the development of synthetic miRNA to beef up the presence of these small RNAs. Low levels of miRNA are recorded in a variety of cancers, and adding substitute miRNA may prove to be a significant new development field.

"The discovery of miRNAs represents a paradigm changing event in biology and medicine of a magnitude that only occurs once every decade or two," said Matt Winkler CEO/CSO of Asuragen. "They likely will become a major new class of drugs."


- check out the press release

Related Articles:
Asuragen rounds up $49M in first round. Report
Asuragen outlines start-up plans. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."